RecruitingNCT05823532
Infliximab or placebo and brain reward responses in schizophrenia
About this title
Read the official source — NCT05823532Medication studyAges 18–55United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Atlanta and 1 more locationSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 18, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Emory University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05823532
- Official title
Show the full official title
Targeting Inflammation-Induced Changes in Brain Reward Signaling and Motivational Deficits in Patients With Schizophrenia Using an Anti-Inflammatory Challenge.
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Atlanta
Questions about this study
Who is behind this study?
The study sponsor is Emory University, a university.
Does this study involve medication?
Yes. The study involves medication, including Infliximab and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
